Full Study Title: AntiPhospholipid Syndrome Low-molecular-weight Heparin Pregnancy Loss Evaluation: The Pilot Study
Principal Investigators: Leslie Skeith, Marc Rodger
Funding: CanVECTOR Pilot, LEO (Leo Pharma)
Design: Open-label pilot RCT of antepartum prophylaxis with LMWH and ASA versus ASA alone in women with confirmed antiphospholipid syndrome (APS) and a history of past pregnancy loss
For more information: NCT03100123 https://clinicaltrials.gov/
Full Study Title: Predicting Bleeding Risk on Anticoagulant Therapy for Venous Thromboembolism
Principal Investigator: Phil Wells
Funding: HSF (Heart and Stroke Foundation of Canada)
Design: Cohort study of VTE (Venous Thromboembolism) patients on anticoagulants to derive a decision rule for bleeding
For more information: NCT00788736 https://clinicaltrials.gov/
Published Abstract: ISTH 2017 - Research and Practice in Thrombosis and Haemostasis: Bleed Risk
Full Study Title: Comparison of Bleeding Risk Between Rivaroxaban and Apixaban
Principal Investigator: Lana Castellucci
Funding: CanVECTOR Pilot
Design: Open-label pilot RCT (randomized clinical trial) comparing bleeding risk with rivaroxaban versus apixaban
For more information: NCT02559856 https://clinicaltrials.gov/
Full Study Title: Comparison of Oral Anticoagulants for Extended VEnous Thromboembolism
Principal Investigators: Lana Castellucci, Thomas Ortel, David Garcia
Patient Partner: Ryan O'Connell
Funding: PCORI (Patient-Centered Outcomes Research Institute)
Design: Pragmatic open-label RCT (randomized clinical trial) comparing the safety and efficacy of rivaroxaban, apixaban and warfarin for the long-term treatment of unprovoked VTE (venous thromboembolism).
For more information: NCT03196349 https://clinicaltrials.gov/
Full Study Title: Perioperative Anticoagulant Use for Surgery Evaluation Study
Principal Investigator: Jim Douketis
Funding: CIHR (Canadian Institutes of Health Research), HSF (Heart and Stroke Foundation of Canada)
Design: Prospective cohort study of patients with atrial fibrillation on new oral anticoagulants requiring interruption for elective surgery/procedure; looking to develop a safer perioperative protocol
For more information: NCT02228798 https://clinicaltrials.gov/
Full Study Title: A Safety and Effectiveness of LMWH vs Placebo Bridging Therapy for Patients on Long Term Warfarin Requiring Temporary Interruption of Warfarin
Principal Investigator: Michael Kovacs
Funding: CIHR (Canadian Institutes of Health Research), Pfizer
Design: Double-blind RCT (randomized clinical trial) of post-procedure bridging with LMWH (low-molecular-weight heparin) versus placebo for patients on long-term warfarin who require temporary interruption of warfarin
For more information: NCT00432796 https://clinicaltrials.gov/
Full Study Title: D-dimer Testing Tailored to Clinical Pretest Probability in Suspected Pulmonary Embolism
Principal Investigator: Clive Kearon
Funding: CIHR (Canadian Institutes of Health Research)
Design: Prospective cohort study to assess a new diagnostic management strategy for suspected pulmonary embolism in outpatients
For more information: NCT02483442 https://clinicaltrials.gov/
Full Study Title: Clinical Predictors for Venous Thromboembolism in Patients With a History of Thrombosis
Principal Investigators: Gregoire Le Gal
Funding: HSF (Heart and Stroke Foundation of Canada)
Design: Prospective cohort of patients with a history of thrombosis and new symptoms of VTE (venous thromboembolism); evaluating the performance of current clinical decision rules with this population
For more information: NCT02297373 https://clinicaltrials.gov/
Full Study Title: Rivaroxaban Anticoagulation for Superficial Vein Thrombosis
Principal Investigator: Clive Kearon
Funding: Bayer
Design: Double-blind RCT (randomized clinical trial) of rivaroxaban versus placebo for treatment of superficial vein thrombosis
For more information: NCT02123524 https://clinicaltrials.gov/
Full Study Title: Rivaroxaban for Antiphospholipid Antibody Syndrome
Principal Investigators: Mark Crowther, Kimberly Legault
Funding: HSF (Heart and Stroke Foundation of Canada), Bayer
Design: Pilot prospective management study of rivaroxaban for patients with antiphospholipid antibody syndrome
For more information: NCT02116036 https://clinicaltrials.gov/
Full Study Title: Reduction to Preventive Doses of Enoxaparin After 3 to 6 Months of Treatment With Blood Thinners for Cancer-associated Blood Clots
Principal Investigator: Vicky Tagalakis
Funding: Sanofi
Design: Pilot management cohort study involving cancer patients with DVT (deep vein thrombosis) or PE (pulmonary embolism); step down to prophylactic doses of enoxaparin after 3-6 months of full-dose treatment
For more information:NCT02752607 https://clinicaltrials.gov/